{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:23:55Z","timestamp":1791951835490,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmmc-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.yjmcc.2020.05.007","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T21:59:34Z","timestamp":1589579974000},"page":"63-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":242,"special_numbering":"C","title":["p38 MAPK inhibition: A promising therapeutic approach for COVID-19"],"prefix":"10.1016","volume":"144","author":[{"given":"Joseph M.","family":"Grimes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin V.","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.yjmcc.2020.05.007_bb0005","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0010","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0015","first-page":"1","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan","author":"Ruan","year":"2020","journal-title":"China. Intensive Care Med."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0020","doi-asserted-by":"crossref","first-page":"9652","DOI":"10.3892\/mmr.2017.7811","article-title":"Modulation of mitogen-activated protein kinase attenuates sepsis-induced acute lung injury in acute respiratory distress syndrome rats","volume":"16","author":"Fang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0025","first-page":"1685","article-title":"Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. circulation","volume":"99","author":"Ma","year":"1999","journal-title":"Am. Heart Assoc."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.cr.7290257","article-title":"Activation and signaling of the p38 MAP kinase pathway","volume":"15","author":"Zarubin","year":"2005","journal-title":"Cell Res. Nat. Publ. Group"},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0035","article-title":"Angiotensin converting enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System","author":"Mahmoud","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0040","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1681\/ASN.2016101066","article-title":"Immunologic Effects of the Renin-Angiotensin System","volume":"28","author":"Crowley","year":"2017","journal-title":"J. Am. Soc. Nephrol. JASN."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bph.12159","article-title":"ACE2, angiotensin-(1\u20137) and Mas receptor axis in inflammation and fibrosis","volume":"169","author":"Silva","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0050","first-page":"481","article-title":"p38 Mitogen-activated protein kinase inhibition ameliorates angiotensin II\u2013Induced Target Organ Damage","volume":"49","author":"Joon-Keun","year":"2007","journal-title":"Hypertens. Am. Heart Assoc."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0055","first-page":"409","article-title":"Angiotensin-converting enzyme 2-angiotensin (1\u20137)-Mas axis prevents pancreatic acinar cell inflammatory response via inhibition of the p38 mitogen-activated protein kinase\/nuclear factor-\u03baB pathway","volume":"41","author":"Yu","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0060","first-page":"35466","article-title":"Reactive Oxygen Species and p38 Mitogen-activated Protein Kinase Mediate Tumor Necrosis Factor \u03b1-Converting Enzyme (TACE\/ADAM-17) Activation in Primary Human Monocytes","volume":"286","author":"Scott","year":"2011","journal-title":"J Biol Chem. Am. Soc. Biochem. Mol. Biol."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0065","article-title":"Association of inpatient use of angiotensin converting enzyme inhibitors and Angiotensin II Receptor Blockers with mortality among patients with hypertension hospitalized with COVID-19","author":"Zhang","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0070","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0075","first-page":"785","article-title":"7a protein of severe acute Respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 Mitogen-Activated Protein Kinase","volume":"80","author":"Kopecky-Bromberg","year":"2006","journal-title":"J. Virol. Am. Soc. Microbiol. J."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1074\/jbc.M113.469239","article-title":"Inhibition of p38 Mitogen-activated Protein Kinase Impairs Influenza Virus-induced Primary and Secondary Host Gene Responses and Protects Mice from Lethal H5N1 Infection","volume":"289","author":"B\u00f6rgeling","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0085","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.1128\/JVI.00804-10","article-title":"Toll-Like Receptor 4-mediated activation of p38 Mitogen-activated Protein Kinase is a determinant of respiratory virus entry and tropism","volume":"84","author":"Marchant","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0090","doi-asserted-by":"crossref","first-page":"C1073","DOI":"10.1152\/ajpcell.00364.2012","article-title":"Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1\/2 signaling","volume":"304","author":"Xiao","year":"2013","journal-title":"Am. J. Phys. Cell Physiol."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004320","article-title":"The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis","volume":"10","author":"Jimenez-Guarde\u00f1o","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0100","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"The Lancet. Elsevier"},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0105","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with Covid-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10234","key":"10.1016\/j.yjmcc.2020.05.007_bb0110","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0115","first-page":"7673","article-title":"Arterial Thrombosis is accompanied by elevated MITOGEN-Activated Protein Kinase (MAPK) and Cyclooxygenase-2 (COX-2) expression via Toll-Like Receptor 4 (TLR-4) Activation by S100A8\/A9","volume":"24","author":"Chen","year":"2018","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0120","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.yjmcc.2010.10.021","article-title":"The p38 mitogen-activated protein kinase pathway\u2013a potential target for intervention in infarction, hypertrophy, and heart failure","volume":"51","author":"Marber","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0125","doi-asserted-by":"crossref","first-page":"L333","DOI":"10.1152\/ajplung.00038.2015","article-title":"The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension","volume":"309","author":"Church","year":"2015","journal-title":"Am. J. Physiol-Lung Cell Mol. Physiol. Am. Physiol. Soc."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0130","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jss.2006.01.028","article-title":"p38 mitogen-activated protein kinase mediates the sustained phase of hypoxic pulmonary vasoconstriction and plays a role in phase I vasodilation","volume":"134","author":"Morrell","year":"2006","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/bcp.12063","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers","volume":"76","author":"Barbour","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0140","first-page":"515","article-title":"Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide\u2013Mediated Vasodilatation and reduces inflammation in Hypercholesterolemia. Circulation","volume":"123","author":"Joseph","year":"2011","journal-title":"Am. Heart Assoc."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0145","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.2016.3609","article-title":"Effect of Losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: A randomized clinical trial","volume":"315","author":"O\u2019Donoghue","year":"2016","journal-title":"JAMA. Am. Med. Assoc."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb0150","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/CCM.0000000000001132","article-title":"A randomized dose-escalation study of the safety and anti-inflammatory activity of the p38 mitogen-activated protein kinase inhibitor dilmapimod in severe trauma subjects at risk for Acute Respiratory Distress Syndrome","volume":"43","author":"Christie","year":"2015","journal-title":"Crit. Care Med."},{"issue":"6","key":"10.1016\/j.yjmcc.2020.05.007_bb1000","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","article-title":"Angiotensin-II mediates ACE2 Internalization and Degradation through an Angiotensin-II type I receptor-dependent mechanism","volume":"64","author":"Deshotels","year":"2014","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.yjmcc.2020.05.007_bb2000","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2353\/ajpath.2008.070762","article-title":"Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK\/p38 MAP kinase pathway","volume":"172","author":"Kova","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.yjmcc.2020.05.007_bb3000","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104850","article-title":"Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-\u03baB signaling pathway","author":"Ma","year":"2020","journal-title":"Pharmacol. Res."}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282820301899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282820301899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T20:31:21Z","timestamp":1758313881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282820301899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":33,"alternative-id":["S0022282820301899"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2020.05.007","relation":{},"ISSN":["0022-2828"],"issn-type":[{"value":"0022-2828","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"p38 MAPK inhibition: A promising therapeutic approach for COVID-19","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2020.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}